Safety and effectiveness assessment of the surpass evolve (SEASE): A post-market international multicenter study

Juan Vivanco-Suarez, Mahmoud Dibas, Demetrius Klee Lopes, Ricardo A. Hanel, Mario Martínez-Galdámez, Aaron Rodriguez-Calienes, Gustavo M. Cortez, Johanna T. Fifi, Alex Devarajan, Gabor Toth, Thomas Patterson, David Altschul, Vitor M. Pereira, Eileen Liu, Ajit S. Puri, Anna Luisa Kuhn, Waldo R. Guerrero, Priyank Khandelwal, Ivo Bach, Peter KanGautam Edhayan, Curtis Given, Sandra Narayanan, Bradley A. Gross, Mudassir Farooqui, Milagros Galecio-Castillo, Shahram Derakhshani, Santiago Ortega-Gutierrez

Research output: Contribution to journalArticlepeer-review


Background: Flow diverters are the first-line treatment for specific intracranial aneurysms (iA). Surpass Evolve (SE) is a new-generation 64-wire flow diverter with a high braid angle. Current literature on the SE is limited. We aimed to report the first international real-world experience evaluating the safety and effectiveness of the SE. Methods: The Safety and Effectiveness Assessment of the Surpass Evolve (SEASE) was a multicenter retrospective international post-marketing cohort study including consecutive patients treated with SE for iAs between 2020 and 2022. Demographic, clinical, and angiographic data were collected. Primary effectiveness was independent core lab adjudicated complete occlusion rates (Raymond-Roy Class 1) at last follow-up. Primary safety were major ischemic/hemorrhagic events and mortality. Results: In total, 305 patients with 332 aneurysms underwent SE implantation. The patients had a median age of 59 [50-67] years, and 256 (83.9%) were female. The baseline modified Rankin scale score was 0-2 in 291 patients (96.7%). Most aneurysms were unruptured (285, 93.4%) and saccular (309, 93.1%). Previous treatment was present in 76 (22.9%) patients. The median aneurysm size was 5.1 [3.4-9.0] mm, and the median neck width was 3.6 [2.7-5.1] mm. Most aneurysms were in the internal carotid artery C6 ophthalmic segment (126, 38.0%), followed by the communicating segment (58, 17.5%). At median 10.2 [6.4-12.9] months follow-up, 233 (73.0%) aneurysms achieved complete occlusion. After adjusting for confounders, complete occlusion remained consistent. Major stroke and procedure-related mortality were reported in 6 (2%) and 2 (0.7%) cases, respectively. Conclusion: These results demonstrate that SE has a consistently high effectiveness and favorable safety for the treatment of iAs.

Original languageEnglish
Article numberjnis-2024-021503
JournalJournal of NeuroInterventional Surgery
StateAccepted/In press - 2024
Externally publishedYes


  • Aneurysm
  • Flow Diverter
  • Hemorrhage
  • Subarachnoid


Dive into the research topics of 'Safety and effectiveness assessment of the surpass evolve (SEASE): A post-market international multicenter study'. Together they form a unique fingerprint.

Cite this